GeneDx Falls Premarket After Company Slashes '26 Rev View

Dow Jones05-05

By Rob Curran

Shares of GeneDx tumbled premarket after the genetic-testing firm posted a surprisingly wide first-quarter loss and slashed its revenue forecast for the year due to an anticipated of more moderate growth in test volumes.

Its stock fell 41% in premarket trading to $39.87.

Late Monday, the company logged a loss of $63.3 million, or $2.16 a share, wider than $6.5 million, or 23 cents a share, a year earlier, and far wider than the 56 cents a share loss anticipated by analysts at brokerage FactSet.

Revenue rose 17% to $102.3 million, short of the average analyst target of $112.5 million.

For the second quarter, GeneDx forecast an adjusted loss of $5 million on revenue of $110 million to $112 million, shy of the average analyst estimate of $122 million.

For 2026, GeneDx slashed its revenue forecast to a range between $475 million and $490 million from a previous $540 million-to-$555 million estimate, compared to the Wall Street peg of $509.7 million. The company pared its projection for growth in test volumes. The company still anticipates positive adjusted earnings for the year.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

May 05, 2026 06:40 ET (10:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633691977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633691977","market":"sg","top_or_hot":-1,"title":"GeneDx Falls Premarket After Company Slashes '26 Rev View","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of GeneDx tumbled premarket after the genetic-testing firm posted a surprisingly wide first-quarter loss and slashed its revenue forecast for the year due to an anticipated of more moderate growth in test volumes. \n</p>\n<p>\n  Its stock fell 41% in premarket trading to $39.87. \n</p>\n<p>\n  Late Monday, the company logged a loss of $63.3 million, or $2.16 a share, wider than $6.5 million, or 23 cents a share, a year earlier, and far wider than the 56 cents a share loss anticipated by analysts at brokerage FactSet. \n</p>\n<p>\n  Revenue rose 17% to $102.3 million, short of the average analyst target of $112.5 million. \n</p>\n<p>\n  For the second quarter, GeneDx forecast an adjusted loss of $5 million on revenue of $110 million to $112 million, shy of the average analyst estimate of $122 million. \n</p>\n<p>\n  For 2026, GeneDx slashed its revenue forecast to a range between $475 million and $490 million from a previous $540 million-to-$555 million estimate, compared to the Wall Street peg of $509.7 million. The company pared its projection for growth in test volumes. The company still anticipates positive adjusted earnings for the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2026 06:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GeneDx Falls Premarket After Company Slashes '26 Rev View</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeneDx Falls Premarket After Company Slashes '26 Rev View\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-05 18:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of GeneDx tumbled premarket after the genetic-testing firm posted a surprisingly wide first-quarter loss and slashed its revenue forecast for the year due to an anticipated of more moderate growth in test volumes. \n</p>\n<p>\n  Its stock fell 41% in premarket trading to $39.87. \n</p>\n<p>\n  Late Monday, the company logged a loss of $63.3 million, or $2.16 a share, wider than $6.5 million, or 23 cents a share, a year earlier, and far wider than the 56 cents a share loss anticipated by analysts at brokerage FactSet. \n</p>\n<p>\n  Revenue rose 17% to $102.3 million, short of the average analyst target of $112.5 million. \n</p>\n<p>\n  For the second quarter, GeneDx forecast an adjusted loss of $5 million on revenue of $110 million to $112 million, shy of the average analyst estimate of $122 million. \n</p>\n<p>\n  For 2026, GeneDx slashed its revenue forecast to a range between $475 million and $490 million from a previous $540 million-to-$555 million estimate, compared to the Wall Street peg of $509.7 million. The company pared its projection for growth in test volumes. The company still anticipates positive adjusted earnings for the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2026 06:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633691977","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633691977","pubTimestamp":1777977600,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of GeneDx tumbled premarket after the genetic-testing firm posted a surprisingly wide first-quarter loss and slashed its revenue forecast for the year due to an anticipated of more moderate growth in test volumes.Its stock fell 41% in premarket trading to $39.87.Late Monday, the company logged a loss of $63.3 million, or $2.16 a share, wider than $6.5 million, or 23 cents a share, a year earlier, and far wider than the 56 cents a share loss anticipated by analysts at brokerage FactSet.Revenue rose 17% to $102.3 million, short of the average analyst target of $112.5 million.For the second quarter, GeneDx forecast an adjusted loss of $5 million on revenue of $110 million to $112 million, shy of the average analyst estimate of $122 million.For 2026, GeneDx slashed its revenue forecast to a range between $475 million and $490 million from a previous $540 million-to-$555 million estimate, compared to the Wall Street peg of $509.7 million. The company pared its projection for growth i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","WGS":"GeneDx Holdings"},"translate_title":"GeneDx在公司大幅削减26年预期后盘前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":0.9},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of GeneDx tumbled premarket after the genetic-testing firm posted a surprisingly wide first-quarter loss and slashed its revenue forecast for the year due to an anticipated of more moderate growth in test volumes. \n\n\n  Its stock fell 41% in premarket trading to $39.87. \n\n\n  Late Monday, the company logged a loss of $63.3 million, or $2.16 a share, wider than $6.5 million, or 23 cents a share, a year earlier, and far wider than the 56 cents a share loss anticipated by analysts at brokerage FactSet. \n\n\n  Revenue rose 17% to $102.3 million, short of the average analyst target of $112.5 million. \n\n\n  For the second quarter, GeneDx forecast an adjusted loss of $5 million on revenue of $110 million to $112 million, shy of the average analyst estimate of $122 million. \n\n\n  For 2026, GeneDx slashed its revenue forecast to a range between $475 million and $490 million from a previous $540 million-to-$555 million estimate, compared to the Wall Street peg of $509.7 million. The company pared its projection for growth in test volumes. The company still anticipates positive adjusted earnings for the year. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 06:40 ET (10:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633691977","isCrawlerRequest":true}